💊 Oral, Potent, Proven — Enlicitide Redefines LDL Control

Dr RR Baliga's "Got Knowledge Doc" Podkast

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

4d ago 7:03

MP4•Episode home

🚀 A milestone moment in lipid therapeutics!

The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy.

For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊

Safety was comparable to placebo, and effects were rapid, robust, and sustained to 52 weeks. The ongoing CORALreef Outcomes trial will determine its impact on major cardiovascular events. 🔬❤️

Innovation in lipid lowering is accelerating—and patient-centered options are expanding.

#JAMA #LipidManagement #HeFH #CardiovascularHealth #PCSK9 #Enlicitide #Prevention 🌟

784 episodes